Shots:
- The EC has approved neoadj. Tevimbra + Pt-based CT followed by adj. Tevimbra monotx. for adults with resectable NSCLC at high risk of recurrence
- Approval was based on P-III (RATIONALE-315) trial assessing perioperative Tevimbra with CT before surgery vs PBO + CT in NSCLC pts (n=453), which met its dual 1EPs of EFS & major pathologic response at interim analyses, also published in The Lancet Respiratory Medicine & presented at ESMO’24
- Final analysis (mFU of 38.5mos.) showed Tevimbra + CT improved OS, EFS, MPR & pCR, with sustained EFS benefit (HR 0.58), consistent across IRC & investigator assessments; OS & EFS benefits were consistent across subgroups, irrespective of PD-L1, disease stage, or histology; data to be presented at WCLC’25
Ref: Beone Medicine | Image: Beone Medicine | Press Release
Related News:- Royalty Pharma Signs Agreement to Acquire Interest in Amgen’s Imdelltra Royalties from BeOne Medicines for ~$950M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
